Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Financial Statements and Exhibits
Item 9.01 of the Original 8-K to (i) add the Amended and Restated
Security and Pledge Agreement, the Amended and Restated
Intellectual Property Security Agreement and the Amended and
Restated Guaranty, which are being filed as Exhibit 10.2, Exhibit
10.3 and Exhibit 10.4, respectively, to this Form 8-K/A and (ii)
refile in its entirety the Form of Common Stock Purchase Warrant
previously filed as Exhibit 4.3 to the Original 8-K, which is
being filed as Exhibit 4.3 to this Form 8-K/A. Other than as set
forth in this Explanatory Note, this Form 8-K/A does not amend
any other items in the Original 8-K or include any other
modifications to the exhibits included as part of the Original
8-K.
Item 9.01.Financial Statements and Exhibits
(d)Exhibits
|
Exhibit Number |
Description |
|
|
|
|
4.1 |
Senior Secured Note, dated March 23, 2017, by Interpace |
|
4.2 |
Senior Secured Convertible Note, dated March 23, 2017, by |
|
4.3* |
Form of Common Stock Purchase Warrant |
|
10.1 |
Exchange Agreement, dated as of March 22, 2017, by and |
|
10.2* |
Amended and Restated Security and Pledge Agreement, dated |
|
|
|
|
10.3* |
Amended and Restated Intellectual Property Security |
|
10.4* |
Amended and Restated Guaranty, dated as of March 23, 2017, |
|
10.5 |
Termination Agreement, dated as of March 22, 2017, by and |
|
99.1 |
Press Release dated March 23, 2017 |
* Filed herewith
Previously filed
About Interpace Diagnostics Group (NASDAQ:IDXG)
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer. Interpace Diagnostics Group (NASDAQ:IDXG) Recent Trading Information
Interpace Diagnostics Group (NASDAQ:IDXG) closed its last trading session down -0.03 at 2.34 with 385,960 shares trading hands.